A collection of videos, study abstracts, and other resources all focused on giant cell arteritis.
Newer steroid-sparing therapies, such as IL-6 inhibitors and selective JAK1 inhibitors like upadacitinib (Rinvoq), have shown promise in improving remission rates while reducing adverse effects.
The following is a summary of “Population-Based Performance of Inflammatory Markers in Giant...
The following is a summary of “Optic nerve sheath enhancement on orbital MRI in giant cell...
In the SELECT-GCA trial, upadacitinib was found to be superior in comparison to a placebo in patients with giant cell arteritis.
Upadacitinib 15 mg demonstrated convincing results as a treatment for giant cell arteritis in the phase 3 SELECT-GCA trial.
Insights from the leaders in medical research, trending topics in clinical medicine, and perspectives from your colleagues.
Subscribe to our free Newsletters to receive weekly emails, and even get a laugh or two from our medical cartoons.
